Actinogen Medical – executive interview

Actinogen Medical – executive interview

Actinogen Medical — 7 videos in collection

More on this equity

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11β-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

In this interview, chief executive officer Dr Steven Gourlay describes the commercial opportunities and next development steps for Xanamem in Alzheimer’s disease (AD) and for CI in relation to major depressive disorder. He also discusses promising indications of therapeutic activity from a recent analysis of patients in its XanADu study in mild AD with confirmed disease through blood biomarker testing.


You may also be interested in these:

Healthcare

Actinogen Medical – equity proposition

Healthcare

Actinogen Medical – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.